Xencor, Inc. (XNCR) News
Filter XNCR News Items
XNCR News Results
|Loading, please wait...|
XNCR News Highlights
- XNCR's 30 day story count now stands at 15.
- Over the past 18 days, XNCR's stories per day has been in a clear downtrend, falling by about 0.50 per 2 days.
- JNJ, AMP and ARCB are the most mentioned tickers in articles about XNCR.
Latest XNCR News From Around the Web
Below are the latest news stories about Xencor Inc that investors may wish to consider to help them evaluate XNCR as an investment opportunity.
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
The consensus price target hints at a 55.4% upside potential for Xencor (XNCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Xencor} stock has undergone multiple analysts rating changes in the recent past. Xencor Upgradedby ZacksInvestmentResearch on 10/8/2021. In a note to investors, the firm issued a new rating of Strong-Buy. The analysts previously had rating of Hold. The post Xencor (XNCR) Upgradedby ZacksInvestmentResearch to Strong-Buy appeared first on .
Xencor (XNCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
XNCR, ARCB, RRC, and NTR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 7, 2021
Xencor, Inc. (XNCR) and Janssen Biotech, a Johnson & Johnson (JNJ) company, have entered into a global collaboration and license agreement to develop and commercialize plamotamab and novel XmAb B-cell targeting bispecific antibodies. Following the news, shares of the clinical-stage biopharmaceutical company rose 2% in Monday’s extended trading session after closing nearly 5.5% higher during the day. Plamotamab is a CD20 x CD3 XmAb bispecific antibody, which is currently completing a Phase 1 dose-escalation study in patients suffering from CD20-expressing hematologic malignancies, while XmAb B-cell is designed to conditionally activate T cells through the CD28 co-stimulatory receptor.
Xencor (XNCR) partners will J&J (JNJ) to develop and commercialize bispecific antibody candidates against B-cell malignancy. Resultantly, the stock gains.
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced an exclusive collaboration and worldwide license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize plamotamab and novel XmAb® B-cell targeting bispecific antibodies that are desig
Johnson & Johnson's (NYSE: JNJ) Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for global licensing rights with Xencor Inc (NASDAQ: XNCR). The agreement covers Xencor's CD20/CD3 bispecific antibody plamotamab currently in Phase 1 testing against B cell malignancies. The deal will come with up to $1.18 billion in downstream milestones as well as potential royalties in the "mid-teens to low twenties. Janssen will hold exclusive development and
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced five poster presentations at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, being held in Washington, D.C., and virtually November 10-14, 2021. The presentations will include updated clinical results from expansion cohorts in the Phase 1 study o